From: Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
Clinicopathological characteristics | No (%) |
---|---|
All patients | 104 (100.0) |
Age in years (21–79) | |
mean: 56.5 ± 15.4; median: 58.5 | |
Gender | |
Female | 60 (57.7) |
Male | 44 (42.3) |
Primary tumor location | |
Head/neck | 15 (14.4) |
Upper extremity | 18 (17.3) |
Lower extremity | 25 (24.0) |
Trunk | 42 (40.4) |
Hand/foot | 4 (3.8) |
Primary tumor (pT) | |
pT1 | 34 (32.7) |
pT2 | 20 (19.2) |
pT3 | 27 (26.0) |
pT4 | 23 (22.1) |
Sentinel lymph node biopsy status (SNLB) | 60 (57.7) |
No metastases (SNLB-) | 48 (80.0) |
Metastases present (SNLB+) | 12 (20.0) |
Regional lymph nodes status (pN) | |
No metastases (pN-) | 86 (82.7) |
Metastases present (pN+) | 18 (17.3) |
Recurrence | |
No | 87 (83.7) |
Yes | 17 (16.3) |
Distant metastases | |
No | 99 (95.2) |
Yes | 5 (4.8) |